Business Context and Reporting Period
This Form 8-K is a current report filed by Synta Pharmaceuticals Corp. (not Madrigal Pharmaceuticals, Inc., as indicated in the metadata) on September 28, 2010. The filing reports on corporate governance changes effective as of September 28, 2010.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board appointments and related compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size from six to seven members.
- New Appointment: Donald Kufe, M.D., was appointed as a new Class III Director, effective September 28, 2010. His term is set to last until the 2013 annual meeting of stockholders.
- Compensation Grant: Dr. Kufe received a non-qualified stock option to purchase 15,000 shares of common stock at an exercise price of $4.00 per share (the closing price on the grant date).
- Fee Structure: Dr. Kufe is entitled to a prorated annual fee of $30,000 for the period from October 1, 2010, through June 30, 2011.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies are disclosed in this document other than the standard vesting conditions for the stock options granted.
Investor Verification Checklist
- Verify the identity of the registrant as Synta Pharmaceuticals Corp. and confirm the discrepancy with the metadata company name.
- Review the vesting schedule for the 15,000 stock options granted to Dr. Kufe (25% on first anniversary, then 6.25% quarterly).
- Confirm the exercise price of $4.00 per share against the market price on September 28, 2010.
- Check the referenced Director Compensation Policy (Exhibit 10.2 to the June 30, 2009 Form 10-Q) for full terms of service.